Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 3

Sponsor Class

OTHER 3

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Breast 3

Conditions

Breast Neoplasms 3Esophagogastric Cancer 1Breast Cancer Metastases 1

Interventions

Trastuzumab 350Paclitaxel 334Cyclophosphamide 315Docetaxel 291Capecitabine 181Doxorubicin 180Letrozole 166Tamoxifen 145Bevacizumab 124Fulvestrant 118Carboplatin 118exemestane 111Lapatinib 111Anastrozole 111Radiotherapy 105Epirubicin 104Gemcitabine 97palbociclib 84Exercise 78Vinorelbine 77Fluorouracil 77Surveys and Questionnaires 71pertuzumab 67Filgrastim 64Albumin-Bound Paclitaxel 64eribulin 55Magnetic Resonance Spectroscopy 55Everolimus 52Blood Specimen Collection 51Zoledronic Acid 50

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Breast Neoplasms × zirconium-89-trastuzumab × Clear all
NCT01565200 2025-03-31

ZEPHIR

Jules Bordet Institute

Phase 2 Completed
90 enrolled
Breast

Breast Neoplasms

NCT01832051 2015-11-05

Clinical Value of 89Zr-trastuzumab PET

University Medical Center Groningen

Phase 2 Completed
20 enrolled
Breast

Breast Neoplasms

NCT01081600 2013-05-14

AUY922

University Medical Center Groningen

Completed
7 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡